^
Association details:
| Biomarker: | NRAS Q61 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Mektovi (binimetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
Published date:
02/26/2021
Excerpt:
Patients with NRAS-mutated tumors, except melanoma, were enrolled in subprotocol Z1A, a single-arm study evaluating binimetinib 45 mg twice daily….A NRAS codon 61 mutated colorectal cancer patient had an unconfirmed PR, and two other NRAS codon 61 mutated colorectal patients had stable disease for at least 12 months. In an exploratory analysis, colorectal cancer patients bearing a NRAS codon 61 mutation (n = 8) had a significantly longer OS (p = 0.03) and PFS (p = 0.007) than those with codon 12 or 13 mutations (n = 16).
DOI:
10.1158/1078-0432.CCR-21-0066
Trial ID:
